- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - June 2024

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Tirzepatide (Mounjaro®) has been accepted for restricted use for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults. The restriction limits use to adults with BMI ≥30 kg/m2 and at least one weight-related comorbidity. It is noted that a lower BMI may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population. NICE guidance is expected to be published on October, and it is expected that specialist weight management services would be responsible for providing this medication for this indication.

Last month, budesonide/formoterol (Symbicort®) was accepted for restricted use as a reliever therapy for adults and adolescents (12 years and older) with mild asthma. The restriction limits use to for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.